


Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

The Facts

Amyloidosis refers to a group of deposition diseases in which proteins with unstable structures **misfold and aggregate into amyloid fibrils** that deposit in different organs and tissues.^{1,2}

ATTR-CM is a **life-threatening, underdiagnosed** type of cardiac amyloidosis that is associated with heart failure. The unstable, misfolded proteins can build up in your heart and other parts of your body, causing the heart muscle to stiffen over time, eventually leading to heart failure.^{1,2}



Artistic rendering for visual affect only.

Transthyretin, a protein produced primarily by the liver, dissociates into monomers, which misfold and aggregate into amyloid fibrils. When the fibrils deposit in the heart, this can cause ATTR-CM.


There are two sub-types of ATTR-CM:



Hereditary, or variant ATTR-CM (hATTR) is inherited from a relative and is caused by a mutation in the gene that produces the transthyretin protein. It affects both men and women, with symptom onset occurring in people as early as their 50s or 60s. In the U.S., the most common type (V122I) is found almost exclusively in African Americans.¹⁻⁶

Wild-type ATTR-CM (wtATTR) is associated with aging and is thought to be the most common form of ATTR-CM. This form most often affects men over the age of 60 and is not caused by a genetic mutation.¹⁻⁶

Once diagnosed, the average life expectancy for people with ATTR-CM is approximately 2 to 3.5 years depending on sub-type.⁷



A Difficult Road to Diagnosis




ATTR-CM is believed to be **rare** and **significantly under or misdiagnosed** though the actual number of people with the disease is currently unknown.⁸



Awareness of ATTR-CM is low within the physician community, and as a result, continues to be significantly underdiagnosed. Often ATTR-CM is diagnosed only after symptoms have become severe.⁸

Signs and Symptoms May Include:^{1,11-19}



Patients should talk to their cardiologist about ATTR-CM if they have heart failure and experience any of the signs or symptoms described above.

How is ATTR-CM diagnosed?

ATTR-CM is suspected based on the signs and symptoms presented, as well as results from ECHO, ECG and/or Cardiac MRI.^{9,10}

Once another form of cardiac amyloidosis (light chain amyloidosis) is ruled out by blood and urine analysis, the following tests can contribute to the diagnosis of ATTR-CM following clinical suspicion:^{9,10}



NUCLEAR SCINTIGRAPHY (NON-INVASIVE DIAGNOSTIC TEST TO CONFIRM PRESENCE OF AMYLOID IN THE HEART)



CARDIAC BIOPSY (AN INVASIVE TEST TO CONFIRM THE PRESENCE OF TTR AMYLOID DEPOSITS)



GENETIC TESTING USED TO DETERMINE IF THE DISEASE IS HEREDITARY DUE TO A MUTATION IN THE TTR GENE

Treatment Challenges

Until recently, there were no medicines approved for the treatment of ATTR-CM. Historically, management options were limited to symptom management, and in rare cases, heart or heart and liver transplant.²



Education, awareness, and treatment are critical to improving the diagnosis and care of people affected by ATTR-CM.

1. Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. *Circulation*. 2017;135(14):1357-1377.
 2. Siddiqi OK, Ruberg FL. Cardiac amyloidosis: an update on pathophysiology, diagnosis and treatment. *Trends in Cardiovascular Medicine*. 2017;1050-1738. Siddiqi 2018 an update on pathophysiology.
 3. González-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. *Eur Heart J*. 2015;36(38):2585-2594.
 4. Swiecicki PL, Zhen DB, Mauermann ML, et al. Hereditary ATTR amyloidosis: a single-institution experience with 266 patients. *Amyloid*. 2015;22(2):123-131.
 5. González-López E, López-Sainz Á, Garcia-Pavia P. Diagnosis and Treatment of Transthyretin Cardiac Amyloidosis. *Progress and Hope. Revista Española de Cardiología (English Edition)*. 2017;70(11):991-1004. doi:10.1016/j.rec.2017.05.036.
 6. Mohammed SF, Mirzoyev SA, Edwards WD, et al. Left Ventricular Amyloid Deposition in Patients With Heart Failure and Preserved Ejection Fraction. *JACC: Heart Failure*. 2014;2(2):113-122. doi:10.1016/j.jchf.2013.11.004.
 7. Castano A, Drachman BM, Judge J, et al. Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. *Heart Fail Rev*. 2015; 20(2): 163-178. doi:10.1007/s10741-014-9462-7.
 8. Rapezzi C, Lorenzini M, Longhi S, et al. Cardiac amyloidosis: the great pretender. *Heart Failure Reviews*. 2015;20(2):117-124.
 9. Gilmore JD, Maurer MS, Falk RH, et al. Non-biopsy diagnosis of cardiac transthyretin amyloidosis. *Circulation*. 2016;133(24):2404-2412.
 10. Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. *Orphanet J Rare Dis*. 2013;8:31.
 11. Geller HJ, Singh A, Alexander KM, et al. Association between ruptured distal biceps tendon and wild-type transthyretin cardiac amyloidosis.
 12. Nativi-Nicolau J, Maurer MS. Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common types. *Curr Opin Cardiol*. 2018;33(5):571-579.
 13. Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. *Circulation*. 2012;126(10):1286-1300.
 14. Bishop E, Brown EE, Fajardo J, et al. Seven factors predict a delayed diagnosis of cardiac amyloidosis. *Amyloid*. 2018;doi:10.1080/13506129.2018.1498782. *JAMA*. 2017;318(10):962-963.
 15. Coelho T, Maurer MS, Suhr OB. THAOS – the transthyretin amyloidosis outcomes survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. *Curr Med Res Opin*. 2013;29(1):63-76.
 16. Westermark P, Westermark GT, Suhr OB, Berg S. Transthyretin-derived amyloidosis: probably a common cause of lumbar spinal stenosis. *Ups J Med Sci*. 2014;119(3):223-228.
 17. Yanagisawa A, Ueda M, Sueyoshi T, et al. Amyloid deposits derived from transthyretin in the ligamentum flavum as related to lumbar spinal canal stenosis. *Mod Pathol*. 2015;28(2):201-207.
 18. Rubin J, Alvarez J, Teruya S. Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloid diagnosis: can we identify affected patients earlier? *Amyloid*. 2017;24(4):226-230.
 19. Maurer MS, Elliott P, Merlini G, et al. Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). *Circulation: Heart Failure*. 2017;10(6). doi:10.1161/circheartfailure.116.003815.



Breakthroughs that change patients' lives™